Will 2025 be a tipping point to unlock innovation in pharma commercialization?

Data, tech, and Artificial Intelligence (AI) are set to revolutionize the way drugs are developed and commercialized. We’re already seeing glimpses of that potential today, as pharma companies begin to pilot and validate how these new capabilities can benefit their teams and workflows.

AI promises so much in terms of delivering greater speed, efficiencies, insights, and value. It’s exciting, but also uncertain, with many companies struggling to transform their technological investments into tangible and scalable returns.

At Inizio, we partner with clients every day as they seek to use innovative solutions to address their pain points – from deriving smart insights from vast and disparate datasets to drive their decision-making, to equipping their teams and stakeholders with the most effective tools and insights to support healthcare professionals or patients achieve optimal outcomes.

“The key to unlocking the full potential of data, tech, and AI for pharma lies in aligning technological investments with strategic requirements, building robust data ecosystems, and fostering a culture of collaboration and learning across teams. Companies that prioritize human expertise alongside innovation will not only scale faster but also create sustainable value for healthcare professionals and patients alike.”

– Mary-Kate McGarry, VP, Corporate and Global Strategy, Inizio

What will you find in this report?

Insights from industry veterans and commercialization experts on the current state of the industry.
A spotlight on key trends for 2025, featuring expert perspectives from Inizio leaders worldwide and recommendations for teams looking to stay ahead of the AI curve.

Download the report below.

Ver más información de Inizio Engage.

Jump to a slide with the slide dots.

Nuvera launches expanded data-driven solutions and grows leadership team to elevate the patient and HCP experience.

Nuvera expands its data-driven solutions and strengthens its leadership team to enhance patient and HCP treatment experiences.

Inizio Engage choose Egg as Patient Support Program implementation partner in Italy.

After a review of potential Patient Support Program (PSP) partners in Italy, Inizio Engage has formed a collaboration with Egg, head quartered in Mila

Steve Cottrell takes on the role of Chief Growth Officer at Inizio Engage

Inizio Engage is pleased to announce that Steve Cottrell has been selected for the role of Chief Growth Officer (CGO) at Inizio Engage.